MedTrace Logo

Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

NCT06660147 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 327

Last updated 2024-10-28

No results posted yet for this study

Summary

This study aims to understand whether it is possible to predict the effectiveness of maintenance treatment with PARP inhibitors following first-line chemotherapy in ovarian cancer, and thus better target the patients who benefit from this treatment

Conditions

Sponsors & Collaborators

  • ARCAGY/ GINECO GROUP

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-11
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • France
  • Monaco

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06660147 on ClinicalTrials.gov